|
|
|
European Biopharmaceutical Review
|
<p align="justify" class="feature">The term 'amyloid' was introduced in scientific literature in the mid-19th Century to describe macroscopic abnormalities in organs and tissues of patients afflicted with a variety of clinical syndromes. It took almost a century to realise that these amyloid deposits consisted of fibrillar ultrastructures when examined by electron microscopy (see Figure 1).
Subsequently, numerous studies followed which confirmed that deposits of diverse origin show a similar, fibrillar submicroscopic structure consisting of bundles of straight and rigid fibrils. Several amyloid disorders have since been discovered. Although diverse in etiology and pathogenesis, they all demonstrate this accumulation of large fibrillary protein aggregates which interfere with specificorgan functions.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Avantor® Enters into Distribution Agreement to Supply Agilent Technologies’ Chemistries and Supplies Division products in the U.S. and Canada
Enabling analytical chemistry workflow laboratories full access to Agilent Technologies’ Chemistries & Supplies Division (CSD) portfolio - focusing on chromatography columns, sample preparation products, chemical standards, and spectroscopy supplies through Avantor’s leading digital and direct channels.
More info >> |
|
 |
White Papers |
 |
|
Future-proofing serialization solutions: the importance of strong level 3 capabilities
Adents
The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >> |
|
|
.jpg)
